Ribose (Furanose)

Ribose (Furanose)

SCHEMBL1531264

Cc1ncnc2nc[nH]c12.OC[C@H]1OC(O)[C@@H](O)[C@@H]1O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.40
CYP3A4 P08684 1/20 0.39
CYP1A2 P05177 2/20 0.39
CDK2 P24941 2/20 0.39
HIF1A Q16665 3/20 0.38
HTT P42858 3/20 0.37
LMNA P02545 2/20 0.37
PDPK1 O15530 2/20 0.37
TP53 P04637 2/20 0.37
LRRK2 Q5S007 2/20 0.37
CHEK1 O14757 1/20 0.37
AURKA O14965 1/20 0.37
CHEK2 O96017 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
PRKACA P17612 1/20 0.37
CCNE1 P24864 1/20 0.37
MARK3 P27448 1/20 0.37
RPS6KA3 P51812 1/20 0.37
PRKCD Q05655 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL12542065 1.00 HSD17B10 (0.40) HSD17B10CYP3A4CYP1A2CDK2HIF1A
Ribose (Furanose) SCHEMBL1682946 1.00 HSD17B10 (0.40) HSD17B10CYP3A4CYP1A2CDK2HIF1A
Ribose (Furanose) SCHEMBL7680729 0.84 CYP3A4 (0.39) HSD17B10CYP3A4CYP1A2CDK2HIF1A
Adenine SCHEMBL7746165 0.84 PI4KA (0.58) CYP3A4CDK2HIF1AHTTLMNA
Adenine SCHEMBL580228 0.84 PI4KA (0.58) CYP3A4CDK2HIF1AHTTLMNA
Ribose (Furanose) SCHEMBL17824409 0.84 ADK (0.40) HSD17B10CYP3A4CYP1A2CDK2HIF1A
Ribose (Furanose) SCHEMBL8605925 0.84 ADK (0.40) HSD17B10CYP3A4CYP1A2CDK2HIF1A
Adenine SCHEMBL38386 0.84 PI4KA (0.58) CYP3A4CDK2HIF1AHTTLMNA
Ribose (Furanose) SCHEMBL831005 0.84 CYP3A4 (0.39) HSD17B10CYP3A4CYP1A2CDK2HIF1A
Adenine SCHEMBL7624128 0.84 PI4KA (0.58) CYP3A4CDK2HIF1AHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2301585-B1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VASCULAR BIOGENICS LTD (IL) 2015-01-07 EP disclosed
US-8835398-B2 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VASCULAR BIOGENICS LTD. (IL) 2014-09-16 US disclosed
US-20140155467-A1 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS VASCULAR BIOGENICS LTD. (IL) 2014-06-05 US disclosed
US-20130295053-A1 Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby VASCULAR BIOGENICS LTD (IL) 2013-11-07 US disclosed
US-20130052165-A1 Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby VASCULAR BIOGENICS LTD. (IL) 2013-02-28 US disclosed
US-20130011367-A1 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis VASCULAR BIOGENICS, LTD. (IL) 2013-01-10 US disclosed
EP-2523681-A1 METHODS OF PRODUCING ADENOVIRUS VECTORS AND VIRAL PREPARATIONS GENERATED THEREBY Vascular Biogenics Ltd. (IL) 2012-11-21 EP disclosed
EP-2301586-B1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VASCULAR BIOGENICS LTD (IL) 2012-09-26 EP disclosed
US-8206743-B2 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VASCULAR BIOGENICS LTD. (IL) 2012-06-26 US disclosed
US-8071740-B2 Isolated polynucleotide sequences; controlling neuvasculization ; cell growth factor VASCULAR BIOGENICS LTD. (IL) 2011-12-06 US disclosed
US-20100081193-A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VASCULAR BIOGENICS LTD. (IL) 2010-04-01 US disclosed
EP-2152317-A2 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS Vascular Biogenics Ltd. (IL) 2010-02-17 EP disclosed
EP-1988926-A2 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS Vascular Biogenics Ltd. (IL) 2008-11-12 EP disclosed
WO-2008132729-A2 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS VASCULAR BIOGENICS LTD. (IL) 2008-11-06 WO disclosed
US-20070286845-A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VASCULAR BIOGENICS LTD. (IL) 2007-12-13 US disclosed
WO-2007096882-A2 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS VASCULAR BIOGENICS LTD. (IL) 2007-08-30 WO disclosed
EP-1814897-A2 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS Vascular Biogenics Ltd. (IL) 2007-08-08 EP disclosed
US-20060204478-A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VASCULAR BIOGENICS LTD. (IL) 2006-09-14 US disclosed
WO-2006051545-A2 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS VASCULAR BIOGENICS LTD. (IL) 2006-05-18 WO disclosed
US-20050186179-A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VASCULAR BIOGENICS LTD. (IL) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050186179-A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VEGFA, CTCF, EDF1 HSD17B10 2551/4885CYP3A4 4879/4885CYP1A2 4877/4885
US-20060204478-A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VEGFA, CTCF, EDF1 HSD17B10 2551/4885CYP3A4 4879/4885CYP1A2 4877/4885
US-20070286845-A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis VEGFA, CTCF, EDF1 HSD17B10 2551/4885CYP3A4 4879/4885CYP1A2 4877/4885
US-20130011367-A1 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis VEGFA, CTCF, EDF1 HSD17B10 2551/4885CYP3A4 4879/4885CYP1A2 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.